TNF and inflammatory bowel disease: Our findings reveal that IBD patients under immunosuppressive medication with anti-TNF antibodies exhibit significantly lower median anti-spike concentrations after basic immunization compared to both HCW control groups and to IBD patients treated with ustekinumab/vedolizumab.